3rd International Brain Stimulation Conference

Conference Co-Chair

Harold A. Sackeim, PhD, Founding Editor, Brain Stimulation, Columbia University, New York, NY, USA

Harold A. SackeimDr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology, College of Physicians and  Surgeons, Columbia University.  He served  as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the founding Editor of the journal, Brain  Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.  He received his first  B.A. from Columbia College, Columbia University (1972), another B.A. and a M.A.  from Magdalen College, Oxford University (1974) and his Ph.D. from the  University of Pennsylvania (1977), where he also completed his clinical  training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977, where he remains today.

His research has concentrated on the neurobiology and treatment of  mood disorders. He has made numerous contributions to the understanding of  pathophysiology of major depression and mania through use of brain imaging  techniques and by examining the role of lateralization of brain function in  normal emotion, neurological disorders, and psychiatric illness. For 30 years,  he led the clinical research on electroconvulsive therapy (ECT) at Columbia  University and the New York State Psychiatric Institute. This work has  identified fundamental factors in this treatment that are responsible for its efficacy and side effects, and has radically altered understanding of both  therapeutics and mechanisms of action. This research program has provided compelling  evidence regarding the localization of the brain circuits involved in  antidepressant effects, and has revamped understanding of the underpinnings of  ECT’s effects on mood, behavior, and cognition. Dr. Sackeim is widely credited  with transforming the use of this treatment worldwide.
Dr. Sackeim has directed programs at the  New York State Psychiatric Institute and New York Presbyterian Hospital in the pharmacological treatment of late-life depression, and in the use of Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS), Deep  Brain Stimulation (DBS) and other forms of focal brain stimulation. Dr. Sackeim  is the inventor of Magnetic Seizure Therapy (MST), now undergoing clinical  trials and has recently developed FEAST (Focal Electrically-Administered  Seizure Therapy. Dr. Sackeim introduced functional brain imaging to the medical  center at Columbia in 1980, and directed a large group using Positron Emission  Tomography (PET) and Magnetic Resonance Imaging (MRI) to study pathophysiology  and treatment effects in mood disorders, anxiety disorders, Lyme disease, substance abuse, Alzheimer’s disease, and normal aging. Other work directed by  Dr. Sackeim involved preclinical, primate research on the functional  significance of structural brain changes (neurogenesis) induced by different  forms of brain stimulation.

Dr. Sackeim is a member  of the editorial board of several journals, and has received many national and  international awards for his research contributions. These include three  Distinguished Investigator Awards from the National Association for Research in Schizophrenia and Depression (NARSAD), a MERIT Award from the National Institute of Mental Health (NIMH), the Joel Elkes International Award from the  American College of Neuropsychopharmacology (ACNP), election as Honorary Fellow  of the American Psychiatric Association, and the Award for Research Excellence  from the New York State Office of Mental Hygiene, Edward Smith Lectureship,  National Institute of Psychobiology, Israel, the lifetime achievement award  form the EEG and CNS Society, and the NARSAD Maddox Falcone Prize for lifetime  achievement in research on affective disorders. He is past President of the  Society of Biological Psychiatry and the Association for Research in Nervous and Mental Disease. He has authored more than 425 publications.